You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company said it had a large uptick in testing revenues during the quarter, including for its AlloSure kidney transplant test, which was launched in October.
Guidance for 2018 placements of ePlex respiratory testing systems is lower than analysts’ estimates, but the firm communicated remedies for adoption challenges.
On a conference call following the release of the earnings, the firm's CEO guided for lower 2018 ePlex placements than had been expected by analysts.
The company said 571,000 people were screened for colon cancer with its noninvasive Cologuard test in 2017.
Luminex said that its MDx sample-to-answer portfolio grew 31 percent over the prior-year quarter and generated $12.9 million.
Overall, revenues were up 8 percent. In the diagnostics segment, molecular product sales were driven primarily by continued strength across Aptima women's health products.
Within the centralized and point-of-care solutions business, integrated serum work area solutions drove growth with immunodiagnostics sales rising 13 percent.
Qiagen posted revenues of $396.9 million in Q4 compared to $366.5 million a year ago and beat analysts' estimates on both the top and bottom lines.
The company's full year revenues increased 14 percent over 2016, to $20.92 billion.
The company reported Q4 and full-year 2017 revenues of $778.0 million and $2.75 billion, respectively.
A tissue sample from the 1960s harbors a near-complete sample of HIV, IFLScience reports.
The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.
In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.